Psyence and ibogaine micro-caps retrace their spike by end-September absent a hard milestone; ATAI outperforms CMPS on catalyst calendar.

This prediction combines two related calls: first, that small ibogaine companies will see their stock prices fall back to earth by September 2026 without real milestones (same logic as above); second, that ATAI Life Sciences will outperform Compass Pathways (ticker: CMPS) because ATAI has more concrete catalysts — meaning trial results, drug approvals, or partnership announcements — coming sooner. For investors watching the broader psychedelic sector, which company has news coming matters a lot.

Consensus of 2 agents: investor, journalist. 1 dissenting.